Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02962349
Other study ID # TRAIN
Secondary ID
Status Recruiting
Phase N/A
First received November 4, 2016
Last updated November 10, 2016
Start date September 2016
Est. completion date December 2020

Study information

Verified date November 2016
Source European Society of Intensive Care Medicine
Contact Fabio S TACCONE, MD, PhD
Phone +3225555587
Email ftaccone@ulb.ac.be
Is FDA regulated No
Health authority Belgium: European Society of Intensive Care medicine
Study type Interventional

Clinical Trial Summary

A Prospective Multicenter Randomized Interventional Study. Blood transfusion can be lifesaving in extreme circumstances, in the absence of life threatening hemorrhage, the indications for transfusion are somewhat controversial. The aim of the current study is to determine whether a"liberal" strategy of maintaining Hb concentrations above 9 g/dL would result in a different neurological outcome when compared to a "restrictive" approach to red-cell transfusion to avoid hemoglobin concentrations < 7 g/dL in critically ill anemic patients (i.e. Hb< 9 g/dL) with acute brain injury.


Description:

Background: Although blood transfusions can be lifesaving in severe hemorrhage, they could also result in several potential complications. As anemia has also been associated with poor outcome in critically ill patients,optimal transfusion trigger is a real challenge for clinicians. This is even more important in patients with acute brain injury who were not specifically evaluated in previous large randomized clinical trials dealing with the optimal transfusion threshold. Neurological patients may be particularly sensitive to anemic brain hypoxia because of the exhausted cerebro-vascular reserve, which adjust cerebral blood flow to tissue oxygen demand.

Methods/Design: The investigators describe herein the methodology of a prospective, multicenter, randomized, pragmatic trial comparing two different strategies to initiate red blood cells transfusions in patients with acute brain injury: a "liberal" strategy, which aims to maintain hemoglobin(Hb) concentrations above 9 g/dL and a "restrictive" approach to blood transfusion that maintains hemoglobin concentrations above 7 g/dL. Target population includes patients suffering from traumatic brain injury (TBI), subarachnoid hemorrhage (SAH) and intracranial hemorrhage (ICH). The primary outcome is neurological outcome, evaluated using extended Glasgow Outcome Scale (eGOS), at 180 days after the initial injury. Secondary outcomes include, amongst all, 28-day survival, intensive care unit (ICU) and hospital length of stay, the occurrence of extra-cerebral organ dysfunction/failure and the development of any infection or thromboembolic events (either venous or arterial). The estimated sample size to demonstrate a reduction in the primary outcome between groups from 50% to 45% is 4610 patients (2305 for each arm). The study will be initiated in 2015 within several European ICUs and conducted over 4 years.

Expected outcomes/Discussion: This trial will assess the impact of two different strategies to administer blood transfusions in a large cohort of critically ill patients with a primary brain injury. The results of this trial may help to better manage blood products and transfusion thresholds in this specific patients‟ population and will provide additional data in some sub-groups of patients at high-risk of brain ischemia, such as those with an intracranial hypertension or developing cerebral vasospasm.


Recruitment information / eligibility

Status Recruiting
Enrollment 4610
Est. completion date December 2020
Est. primary completion date September 2020
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

1. Age =18 years and = 80 years

2. Acute Brain Injury: Traumatic Brain Injury; Subarachnoid Hemorrhage; Intracranial Hemorrhage

3. Glasgow Coma Score (GCS) on randomization< 12

4. Expected ICU stay > 72 hours

5. Hemoglobin (Hb) concentration < 9 g/dL

Exclusion Criteria:

6. Post-anoxic coma; status epilepticus without underlying brain injury; central nervous system (CNS) infections (community-acquired; hospital-acquired; ventriculitis; post-operative)

7. Known previous neurological disease, causing significant cognitive and/or motor handicap

8. ICH due to artero-venous malformation (AVM) or brain tumor

9. Inability (religious reasons) or reduced ability (lack of compatible blood) to receive blood products

10. Active and uncontrolled bleeding at the time of enrollment

11. GCS of 3 with both fixed and dilated pupils; Brain death or imminent death (within 24 hours)

12. Pregnancy

13. Medical need to correct anemia (e.g. active coronary disease or severe cardiac disease) with target Hb levels > 9 g/dL

14. DNE (do not escalate) orders

15. Previous adverse event with transfusion

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care


Intervention

Biological:
Red blood cell transfusion
Red blood cell transfusion at various doses

Locations

Country Name City State
Belgium All Centers From All Over the World Willing to Contribute Are Welcome Brussels

Sponsors (1)

Lead Sponsor Collaborator
European Society of Intensive Care Medicine

Country where clinical trial is conducted

Belgium, 

References & Publications (10)

Blumberg N, Heal JM. Immunomodulation by blood transfusion: an evolving scientific and clinical challenge. Am J Med. 1996 Sep;101(3):299-308. Review. — View Citation

Carson JL, Duff A, Poses RM, Berlin JA, Spence RK, Trout R, Noveck H, Strom BL. Effect of anaemia and cardiovascular disease on surgical mortality and morbidity. Lancet. 1996 Oct 19;348(9034):1055-60. — View Citation

Carson JL, Poses RM, Spence RK, Bonavita G. Severity of anaemia and operative mortality and morbidity. Lancet. 1988 Apr 2;1(8588):727-9. — View Citation

Fransen E, Maessen J, Dentener M, Senden N, Buurman W. Impact of blood transfusions on inflammatory mediator release in patients undergoing cardiac surgery. Chest. 1999 Nov;116(5):1233-9. — View Citation

Hare GM. Anaemia and the brain. Curr Opin Anaesthesiol. 2004 Oct;17(5):363-9. — View Citation

Hébert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, Tweeddale M, Schweitzer I, Yetisir E. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med. 1999 Feb 11;340(6):409-17. Erratum in: N Engl J Med 1999 Apr 1;340(13):1056. — View Citation

Ness PM. Transfusion medicine: an overview and update. Clin Chem. 2000 Aug;46(8 Pt 2):1270-6. Review. — View Citation

Toy P, Feiner J, Viele MK, Watson J, Yeap H, Weiskopf RB. Fatigue during acute isovolemic anemiain healthy, resting humans. Transfusion. 2000 Apr;40(4):457-60. — View Citation

Vincent JL, Baron JF, Reinhart K, Gattinoni L, Thijs L, Webb A, Meier-Hellmann A, Nollet G, Peres-Bota D; ABC (Anemia and Blood Transfusion in Critical Care) Investigators.. Anemia and blood transfusion in critically ill patients. JAMA. 2002 Sep 25;288(12):1499-507. — View Citation

Vincent JL, Sakr Y, Sprung C, Harboe S, Damas P; Sepsis Occurrence in Acutely Ill Patients (SOAP) Investigators.. Are blood transfusions associated with greater mortality rates? Results of the Sepsis Occurrence in Acutely Ill Patients study. Anesthesiology. 2008 Jan;108(1):31-9. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Neurological outcome at 180 days after brain injury neurological outcome evaluated using extended Glasgow Outcome Scale (eGOS) 180 days No
Secondary 28-day survival parameter 1 Monitoring eGOS changes over time 28 days No
Secondary 28-day survival parameter 2 Monitoring mRS changes over time 28 days No
Secondary ICU and hospital length of stay length of stay 28 days No
Secondary The occurrence of extra-cerebral organ dysfunction/failure Extra-cerebral organ dysfunction/failure: composite outcome (death and/or organ dysfunction/failure) 28 days No
Secondary Infection rate The development of any infection or thromboembolic events (either venous or arterial) 28 days No
See also
  Status Clinical Trial Phase
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT05503316 - The Roll of Balance Confidence in Gait Rehabilitation in Persons With a Lesion of the Central Nervous System N/A
Completed NCT04356963 - Adjunct VR Pain Management in Acute Brain Injury N/A
Completed NCT03418129 - Neuromodulatory Treatments for Pain Management in TBI N/A
Terminated NCT03698747 - Myelin Imaging in Concussed High School Football Players
Recruiting NCT05130658 - Study to Improve Ambulation in Individuals With TBI Using Virtual Reality -Based Treadmill Training N/A
Recruiting NCT04560946 - Personalized, Augmented Cognitive Training (PACT) for Service Members and Veterans With a History of TBI N/A
Completed NCT05160194 - Gaining Real-Life Skills Over the Web N/A
Recruiting NCT02059941 - Managing Severe Traumatic Brain Injury (TBI) Without Intracranial Pressure Monitoring (ICP) Monitoring Guidelines N/A
Recruiting NCT03940443 - Differences in Mortality and Morbidity in Patients Suffering a Time-critical Condition Between GEMS and HEMS
Recruiting NCT03937947 - Traumatic Brain Injury Associated Radiological DVT Incidence and Significance Study
Completed NCT04465019 - Exoskeleton Rehabilitation on TBI
Recruiting NCT04530955 - Transitioning to a Valve-Gated Intrathecal Drug Delivery System (IDDS) N/A
Recruiting NCT03899532 - Remote Ischemic Conditioning in Traumatic Brain Injury N/A
Suspended NCT04244058 - Changes in Glutamatergic Neurotransmission of Severe TBI Patients Early Phase 1
Completed NCT03307070 - Adapted Cognitive Behavioral Treatment for Depression in Patients With Moderate to Severe Traumatic Brain Injury N/A
Recruiting NCT04274777 - The Relationship Between Lipid Peroxidation Products From Traumatic Brain Injury and Secondary Coagulation Disorders
Withdrawn NCT05062148 - Fundamental and Applied Concussion Recovery Modality Research and Development: Applications for the Enhanced Recovery N/A
Withdrawn NCT04199130 - Cognitive Rehabilitation and Brain Activity of Attention-Control Impairment in TBI N/A
Withdrawn NCT03626727 - Evaluation of the Efficacy of Sodium Oxybate (Xyrem®) in Treatment of Post-traumatic Narcolepsy and Post-traumatic Hypersomnia Early Phase 1